Wall Street Zen Downgrades Option Care Health (NASDAQ:OPCH) to Hold

Option Care Health (NASDAQ:OPCH) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

OPCH has been the subject of several other research reports. Stephens upgraded Option Care Health to a “strong-buy” rating in a report on Thursday, December 11th. National Bank Financial set a $37.00 price target on shares of Option Care Health in a research note on Tuesday, January 27th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $37.00 price objective on shares of Option Care Health in a research note on Tuesday, January 13th. Weiss Ratings reiterated a “hold (c)” rating on shares of Option Care Health in a report on Monday, December 29th. Finally, Citizens Jmp restated a “market outperform” rating and issued a $38.00 target price (up from $36.00) on shares of Option Care Health in a report on Tuesday, January 13th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.58.

Option Care Health Trading Up 1.8%

NASDAQ:OPCH opened at $32.46 on Friday. The company has a current ratio of 1.53, a quick ratio of 1.05 and a debt-to-equity ratio of 0.87. The stock has a market capitalization of $5.08 billion, a price-to-earnings ratio of 25.36, a PEG ratio of 1.84 and a beta of 0.84. The firm has a fifty day simple moving average of $33.99 and a two-hundred day simple moving average of $30.57. Option Care Health has a 12 month low of $24.24 and a 12 month high of $36.80.

Option Care Health (NASDAQ:OPCH) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.46 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.46. The company had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.46 billion. Option Care Health had a net margin of 3.67% and a return on equity of 18.57%. The business’s revenue was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.44 EPS. Analysts expect that Option Care Health will post 1.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Option Care Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. V Square Quantitative Management LLC purchased a new position in shares of Option Care Health in the 4th quarter worth approximately $25,000. Cornerstone Planning Group LLC boosted its position in Option Care Health by 7,621.4% in the third quarter. Cornerstone Planning Group LLC now owns 1,081 shares of the company’s stock worth $30,000 after purchasing an additional 1,067 shares during the last quarter. Advisory Services Network LLC bought a new position in Option Care Health in the 3rd quarter valued at $35,000. McIlrath & Eck LLC bought a new position in Option Care Health in the 2nd quarter valued at $37,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Option Care Health during the 3rd quarter valued at $38,000. Hedge funds and other institutional investors own 98.05% of the company’s stock.

Option Care Health Company Profile

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.